表纸
市场调查报告书
商品编码
997049

阻塞型睡眠呼吸中止症症候群 (OSA) - KOL的考察,竞争情报,市场分析、预测 (~2030年)

Obstructive Sleep Apnea (OSA) | Primary Research (KOL's Insight) | Competitive Intelligence | Market Analytics & Forecast 2030

出版日期: | 出版商: Mellalta Meets LLP | 英文 152 Pages | 订单完成后即时交付

价格
  • 全貌
  • 简介
  • 目录
简介

根据世界卫生组织(WHO)实施的调查,阻塞型睡眠呼吸中止症症候群 (OSA)的全球患病人数约1亿人。光是美国,OSA的患者数也是约4,200万人。美国,成人的5人有1人是轻度的OSA,15人有1人是中度到重度的OSA。OSA的病例数,由于睡眠相关障碍的患病人数增加,预计在预测期间内增加。

阻塞型睡眠呼吸中止症症候群 (OSA) 患病人数

阻塞型睡眠呼吸中止症症候群 (OSA) 市场规模:各国

本报告提供阻塞型睡眠呼吸中止症症候群 (OSA) 市场相关调查分析,市场趋势,G7病例数,市场机会,市场预测,竞争分析等相关的系统性资讯。

目录

阻塞型睡眠呼吸中止症症候群 (OSA)的背景

  • 阻塞型睡眠呼吸中止症症候群 (OSA)的定义
  • 症状
  • 危险因素
  • 诊断

流行病学估计与预测

与流行病学的调查手法使用的资料来源

  • 美国的阻塞型睡眠呼吸中止症症候群 (OSA)的发病数量
  • 美国的各重症度的阻塞型睡眠呼吸中止症症候群 (OSA)的病例数
  • 美国的阻塞型睡眠呼吸中止症症候群 (OSA)的诊断、治疗病例数
  • 德国的阻塞型睡眠呼吸中止症症候群 (OSA)的发病数量
  • 德国的各重症度的阻塞型睡眠呼吸中止症症候群 (OSA)的病例数
  • 德国的阻塞型睡眠呼吸中止症症候群 (OSA)的诊断、治疗病例数
  • 法国的阻塞型睡眠呼吸中止症症候群 (OSA)的发病数量
  • 法国的各重症度的阻塞型睡眠呼吸中止症症候群 (OSA)的病例数
  • 法国的阻塞型睡眠呼吸中止症症候群 (OSA)的诊断、治疗病例数
  • 义大利的阻塞型睡眠呼吸中止症症候群 (OSA)的发病数量
  • 义大利的各重症度的阻塞型睡眠呼吸中止症症候群 (OSA)的病例数
  • 义大利的阻塞型睡眠呼吸中止症症候群 (OSA)的诊断、治疗病例数
  • 西班牙的阻塞型睡眠呼吸中止症症候群 (OSA)的发病数量
  • 西班牙的各重症度的阻塞型睡眠呼吸中止症症候群 (OSA)的病例数
  • 西班牙的阻塞型睡眠呼吸中止症症候群 (OSA)的诊断、治疗病例数
  • 英国的阻塞型睡眠呼吸中止症症候群 (OSA)的发病数量
  • 英国的各重症度的阻塞型睡眠呼吸中止症症候群 (OSA)的病例数
  • 英国的阻塞型睡眠呼吸中止症症候群 (OSA)的诊断、治疗病例数
  • 日本的阻塞型睡眠呼吸中止症症候群 (OSA)的发病数量
  • 日本的各重症度的阻塞型睡眠呼吸中止症症候群 (OSA)的病例数
  • 日本的阻塞型睡眠呼吸中止症症候群 (OSA)的诊断、治疗病例数

阻塞型睡眠呼吸中止症症候群 (OSA) 的现在的未满足需求

目前治疗范例

  • 阻塞型睡眠呼吸中止症症候群 (OSA)的治疗指南
  • 阻塞型睡眠呼吸中止症症候群 (OSA)的目前治疗方法

新兴治疗药

  • Dronabinol (RespireRx Pharmaceuticals)
  • BAY2586116 (Bayer)
  • AD109 (Apnimed)
  • AD036 (Apnimed)
  • AD128 (Apnimed)
  • THX-110 (Therapix bio)
  • AD182 and AD504 (Apnimed)
  • Lemborexant (Eisai)
  • MK-7264 (Merck)
  • Seltorexant (Janssen)
  • ACT-541468 (Idorsia)
  • SAS0421 (Apnimed)

OSA产品的地位

主要的竞争企业

综合市场预测

主要摘要的结果

  • G7阻塞型睡眠呼吸中止症症候群 (OSA) 综合市场
  • G7阻塞型睡眠呼吸中止症症候群 (OSA) 综合市场:各治疗

市场预测:各国

  • 美国
    • 阻塞型睡眠呼吸中止症症候群 (OSA)的美国市场
    • 阻塞型睡眠呼吸中止症症候群 (OSA)的美国市场:各治疗
  • 德国
    • 阻塞型睡眠呼吸中止症症候群 (OSA)的德国市场
    • 阻塞型睡眠呼吸中止症症候群 (OSA)的德国市场:各治疗
  • 法国
    • 阻塞型睡眠呼吸中止症症候群 (OSA)的法国市场
    • 阻塞型睡眠呼吸中止症症候群 (OSA)的法国市场:各治疗
  • 义大利
    • 阻塞型睡眠呼吸中止症症候群 (OSA)的义大利市场
    • 阻塞型睡眠呼吸中止症症候群 (OSA)的义大利市场:各治疗
  • 西班牙
    • 阻塞型睡眠呼吸中止症症候群 (OSA)的西班牙市场
    • 阻塞型睡眠呼吸中止症症候群 (OSA)的西班牙市场:各治疗
  • 英国
    • 阻塞型睡眠呼吸中止症症候群 (OSA)的英国市场
    • 阻塞型睡眠呼吸中止症症候群 (OSA)的英国市场:各治疗
  • 日本
    • 阻塞型睡眠呼吸中止症症候群 (OSA)的日本市场
    • 阻塞型睡眠呼吸中止症症候群 (OSA)的日本市场:各治疗

市场促进因素与阻碍

附录

关于Mellalta Meets

目录
Product Code: MM202023

Growth of the Prevalence OSA population will contribute to increasing sales in the OSA therapy market over our forecast period. The increase in number of patients with obstructive sleep apnea across the globe will be driving the market of OSA. According to a study conducted by the World Health Organization (WHO), the global prevalence of sleep apnea is around 100 million people. In the U.S. alone, the number of people with OSA is around 42 million. One out of five adults in the U.S. have mild OSA, while one out of 15 have moderate to severe OSA. The number of cases with OSA is expected to increase during our forecast period, primarily due to increasing Prevalence of sleep-related disorders. This is projected to drive the OSA market from 2020 to 2030.

Obstructive sleep apnea (OSA)-also referred to as obstructive sleep apnea-hypopnea-is a sleep disorder that involves cessation or significant decrease in airflow in the presence of breathing effort. It is the most common type of sleep-disordered breathing and is characterized by recurrent episodes of upper airway collapse during sleep. These episodes are associated with recurrent oxyhemoglobin desaturations and arousals from sleep.

Obstructive sleep apnea - OSA Epidemiology

OSA remains significantly under-recognized, as only 20% of cases in the United States according to the AASM and 20% of cases globally have been properly diagnosed. We hold our diagnosed and treatment cases estimates constant over the forecast period, and changes in the number of OSA cases are due to demographic shifts.

The reported rates of psychiatric diagnosis among modafinil users do seem to be higher than the 18.3% (of adults in the USA) stated in the 2016 National (USA) Survey on Drug Use and Mental Health. As per the survey, overall, modafinil was perceived by users as being safe. Modafinil users reported higher levels of illicit drug use and psychiatric diagnosis than would be expected from population-based data. More frequent reported modafinil use was associated with higher numbers of perceived benefits whilst reported frequency of use was not associated with the number of perceived risks, We are expecting 18% of the OSA patients on this therapy in the base year and will subsequently decline as the new therapies entering into the market.

Obstructive Sleep Apnea (OSA) Prevalence Mellalta Meets

Obstructive sleep apnea Market Forecast

The Obstructive Sleep Apnea (OSA) therapy market is expected to experience high growth throughout our study period, increasing from $XX million in 2017 to $XX billion in 2030, representing 17.78% annual growth. Primary drivers of this growth will be uptake of the therapies Modafinil/Armodafinil (Takeda), Solriamfetol/Sunosi (Jazz Pharmaceuticals), Dronabinol (RespireRx Pharmaceuticals), BAY2586116 (Bayer), AD109 (Apnimed), AD036 (Apnimed), AD128 (Apnimed) and THX-110 (Therapix bio), predominantly in the United States.

There are no specific treatments for the treatment Obstructive Sleep Apnea (OSA) and current care treatment for OSA involves CPAP (Continuous Positive Airway Pressure) is which is the leading device therapy for Obstructive Sleep Apnea (OSA). This treatment involves the patient wearing a mask that connects through a hose to a bedside air pump. Although the therapy has demonstrated improvements in patient-reported sleep quality and reductions in daytime sleepiness, around 35% - 65% are non-CPAP compliant. Patients complain of problems including mask discomfort, mask leakage, pressure intolerance, skin irritation, nasal congestion, nasal drying, nosebleeds, claustrophobia, and lack of intimacy. The CPAP therapy accounts for the 70% of the device-treated OSA population share.

Obstructive Sleep Apnea (OSA) Market Size by Country Mellalta Meets

Report Highlights:

  • Obstructive sleep apnea Current Market Trends
  • Obstructive sleep apnea Current & Forecasted Cases across the G7 Countries
  • Obstructive sleep apnea Market Opportunities And Sales Potential for Agents
  • Obstructive sleep apnea Patient-based Market Forecast to 2030
  • Obstructive sleep apnea Untapped Business Opportunities
  • Obstructive sleep apnea Product Positioning Vis-a-vis Competitors' Products
  • Obstructive sleep apnea KOLs Insight

Table of Contents

Obstructive Sleep Apnea Disease Background

  • Obstructive Sleep Apnea Definition
  • Symptoms
  • Risk Factor
  • Diagnosis

Epidemiology Estimated and Forecast to 2030

Epidemiology Research Method & Data Sources Used

  • Incident Cases of Obstructive Sleep Apnea in the United States 2020-2030
  • Cases of Obstructive Sleep Apnea by OSA by severity in the United States 2020-2030
  • Diagnosed & Treatment Cases of Obstructive Sleep Apnea in the United States 2020-2030
  • Incident Cases of Obstructive Sleep Apnea in Germany 2020-2030
  • Cases of Obstructive Sleep Apnea by OSA by severity in Germany 2020-2030
  • Diagnosed & Treatment Cases of Obstructive Sleep Apnea in Germany 2020-2030
  • Incident Cases of Obstructive Sleep Apnea in France 2020-2030
  • Cases of Obstructive Sleep Apnea by OSA by severity in France 2020-2030
  • Diagnosed & Treatment Cases of Obstructive Sleep Apnea in France 2020-2030
  • Incident Cases of Obstructive Sleep Apnea in Italy 2020-2030
  • Cases of Obstructive Sleep Apnea by OSA by severity in Italy 2020-2030
  • Diagnosed & Treatment Cases of Obstructive Sleep Apnea in Italy 2020-2030
  • Incident Cases of Obstructive Sleep Apnea in Spain 2020-2030
  • Cases of Obstructive Sleep Apnea by OSA by severity in Spain 2020-2030
  • Diagnosed & Treatment Cases of Obstructive Sleep Apnea in Spain 2020-2030
  • Incident of Obstructive Sleep Apnea in the United Kingdom 2020-2030
  • Cases of Obstructive Sleep Apnea by OSA by severity in the United Kingdom 2020-2030
  • Diagnosed & Treatment Cases of Obstructive Sleep Apnea in the United Kingdom 2020-2030
  • Incident Cases of Obstructive Sleep Apnea in Japan 2020-2030
  • Cases of Obstructive Sleep Apnea by OSA by severity in Japan 2020-2030
  • Diagnosed & Treatment Cases of Obstructive Sleep Apnea in Japan 2020-2030

Current Unmet Needs in Obstructive Sleep Apnea

Current Treatment Paradigm

  • Treatment guidelines for Obstructive Sleep Apnea
  • Current Therapies for Obstructive Sleep Apnea

Emerging Therapies Chapters

  • Dronabinol (RespireRx Pharmaceuticals)
  • BAY2586116 (Bayer)
  • AD109 (Apnimed)
  • AD036 (Apnimed)
  • AD128 (Apnimed)
  • THX-110 (Therapix bio)
  • AD182 and AD504 (Apnimed)
  • Lemborexant (Eisai)
  • MK-7264 (Merck)
  • Seltorexant (Janssen)
  • ACT-541468 (Idorsia)
  • SAS0421 (Apnimed)

OSA Product Positioning

Key Competitors

Total Market Forecast

Key Summary Findings

  • G7 total Market for Obstructive Sleep Apnea 2020-2030 (USD Million)
  • G7 total Market for Obstructive Sleep Apnea by Therapies 2020-2030 (USD Million)

Market Forecast by Country

  • United States
    • United States Market for Obstructive Sleep Apnea 2020-2030 (USD Million)
    • United States Market for Obstructive Sleep Apnea by Therapies 2020-2030 (USD Million)
  • Germany
    • Germany Market for Obstructive Sleep Apnea 2020-2030 (USD Million)
    • Germany Market for Obstructive Sleep Apnea by Therapies 2020-2030 (USD Million)
  • France
    • France Market for Obstructive Sleep Apnea 2020-2030 (USD Million)
    • France Market for Obstructive Sleep Apnea by Therapies 2020-2030 (USD Million)
  • Italy
    • Italy Market for Obstructive Sleep Apnea 2020-2030 (USD Million)
    • Italy Market for Obstructive Sleep Apnea by Therapies 2020-2030 (USD Million)
  • Spain
    • Spain Market for Obstructive Sleep Apnea 2020-2030 (USD Million)
    • Spain Market for Obstructive Sleep Apnea by Therapies 2020-2030 (USD Million)
  • United Kingdom
    • United Kingdom Market for Obstructive Sleep Apnea 2020-2030 (USD Million)
    • United Kingdom Market for Obstructive Sleep Apnea by Therapies 2020-2030 (USD Million)
  • Japan
    • Japan Market for Obstructive Sleep Apnea 2020-2030 (USD Million)
    • Japan Market for Obstructive Sleep Apnea by Therapies 2020-2030 (USD Million)

Market Drivers & Barriers

Appendix

About Mellalta Meets